Sensitivity analysis: exploring alternative MM mortality data sources
| MM | TAVI | Incremental values | |||||
|---|---|---|---|---|---|---|---|
| Parameter | Costs | Benefits | Costs | Benefits | Costs | Benefits | ICER* |
| PARTNER-B (1 year) | £12 972 (£11 080, £15 092) | 0.75 (0.70, 0.80) | £35 160 (£30 736, £40 248) | 2.02 (1.87, 2.17) | £22 188 | 1.27 | £17 483 |
| PARTNER-B (2 years) | £12 679 (£10 763, £14 669) | 0.71 (0.67, 0.75) | £35 156 (£30 830, £39 808) | 2.02 (1.88, 2.16) | £22 478 | 1.31 | £17 165 |
| PARTNER-B (3 years) | £13 120 (£11 216, £15 339) | 0.78 (0.73, 0.82) | £35 129 (£30 790, £39 969) | 2.02 (1.87, 2.17) | £22 009 | 1.24 | £17 718 |
| PARTNER-B no BAV† | £9233 (£7536, £10 938) | 0.69 (0.66, 0.73) | £35 173 (£30 519, £40 209) | 2.02 (1.87, 2.17) | £25 940 | 1.33 | £19 500 |
| PARTNER-B with BAV† | £13 268 (£11 311, £15 429) | 0.69 (0.65, 0.73) | £35 214 (£30 820, £40 434) | 2.02 (1.87, 2.16) | £21 946 | 1.33 | £16 441 |
| PARTNER-B STS <5% | £16 148 (£13 846, £18 881) | 1.33 (1.27, 1.40) | £35 222 (£30 740, £40 378) | 2.02 (1.86, 2.17) | £19 074 | 0.69 | £27 790 |
| Varadarajan et al | £14 734 (£12 607, £17 054) | 1.09 (1.02, 1.16) | £35 077 (£30 077, £40 329) | 2.02 (1.86, 2.17) | £20 344 | 0.93 | £21 849 |
| Bouma et al | £16 338 (£13 929, £19 119) | 1.38 (1.30, 1.45) | £35 139 (£30 734, £40 192) | 2.02 (1.87, 2.17) | £18 751 | 0.86 | £20 667 |
Data presented as mean, 95% CrI. Time horizon=5 years. TAVI arm based on ADVANCE high-risk group.
*All values to be interpreted as £ per QALY gained.
†Costings altered to reflect alternative assumptions about BAV usage.
BAV, balloon aortic valvuloplasty; CrI, credible interval; ICER, incremental cost-effectiveness ratio; MM, medical management; QALY, quality-adjusted life-years; TAVI, transcatheter aortic valve implantation.